Table 1.
Clinical trials of combination of MAPK pathway targeted therapy and immunotherapy in advanced or metastatic melanoma.
| NCT number | Targeted therapy | Immunotherapy | Status | Trial Phase | Scheduling |
|---|---|---|---|---|---|
| NCT01400451 (150) | Vemurafenib | Ipilimumab | Terminated | Phase I | Concurrent |
| NCT01673854 (151) | Vemurafenib | Ipilimumab | Completed | Phase II | Sequential |
| NCT02200562 | Dabrafenib | Ipilimumab | Terminated | Phase I | Concurrent |
| NCT01767454 (152) | Dabrafenib or dabrafenib + trametinib |
Ipilimumab | Completed | Phase I | Concurrent |
| NCT01245556 | BMS-908662 | Ipilimumab | Completed | Phase I | Concurrent |
| NCT01656642 | Vemurafenib or vemurafenib + cobimetinib |
Atezolizumab | Active, not recruiting | Phase I | Concurrent |
| NCT03178851 | Cobimetinib | Atezolizumab | Recruiting | Phase I | Concurrent |
| NCT02027961 | Dabrafenib or trametinib or dabrafenib + trametinib |
MEDI4736 | Completed | Phase I/II | Concurrent sequential |
| NCT02130466 | Trametinib + dabrafenib | Pembrolizumab | Recruiting | Phase I/II | Concurrent |
| NCT02357732 | Dabrafenib or trametinib or dabrafenib + trametinib |
Nivolumab | Withdrawn | Phase I | Concurrent |
| NCT02818023 | Vemurafenib + cobimetinib | Pembrolizumab | Recruiting | Phase I | Concurrent |
| NCT02858921 | Dabrafenib + trametinib | Pembrolizumab | Recruiting | Phase II | Concurrent; Sequential |
| NCT02625337 | Dabrafenib + trametinib | Pembrolizumab | Recruiting | Phase II | Concurrent |
| NCT02967692 | Dabrafenib + Trametinib | PDR001 | Recruiting | Phase III | Concurrent |
| NCT02902042 | Encorafenib + binimetinib | Pembrolizumab | Recruiting | Phase I/II | Concurrent |
| NCT03554083 | Cobimetinib or vemurafenib + cobimetinib |
Atezolizumab | Recruiting | Phase II | Concurrent |
| NCT02902029 | Cobimetinib + vemurafenib | Atezolizumab | Recruiting | Phase II | Sequential |
| NCT03235245 | Encorafenib + binimetinib | Ipilimumab + nivolumab | Not yet recruiting | Phase II | Sequential |
| NCT02968303 | Vemurafenib + cobimetinib | Ipilimumab + nivolumab | Recruiting | Phase II | Sequential |
| NCT01940809 | Dabrafenib or trametinib or dabrafenib + trametinib |
Ipilimumab or nivolumab or ipilimumab + nivolumab | Active, not recruiting | Phase I | Sequential |
| NCT02224781 | Dabrafenib + trametinib | Ipilimumab + nivolumab | Recruiting | Phase III | Sequential |
| NCT02631447 | LGX818 + MEK162 | Ipilimumab + nivolumab | Recruiting | Phase II | Sequential |
| NCT01603212 | Vemurafenib | IL-2 + Interferon α-2b | Completed | Phase I/II | Concurrent |
| NCT01754376 (153) | Vemurafenib | Aldesleukin | Terminated | Phase II | Concurrent |
| NCT01683188 (154) | vemurafenib | High-does IL-2 | Terminated | Phase IV | Concurrent |
| NCT01943422 | vemurafenib | High-dose Interferon α-2b | Completed | Phase I | Concurrent |
| NCT01959633 | Vemurafenib | PEG-interferon | Recruiting | Phase I/II | Concurrent |
| NCT02354690 | Vemurafenib | Lymphodepleting chemotherapy + TILs+ IL-2 | Active, not recruiting | Phase I/II | Concurrent |
| NCT01659151 | Vemurafenib | Lymphodepletion+ ACT with TIL Infusion +IL-2 | Active, not recruiting | Phase II | Concurrent |
| NCT01585415 (155) | Vemurafenib | Aldesleukin + Young TIL | Terminated | Phase I | Sequential |
| NCT02382549 | Dabrafenib + trametinib | 6MHP (6 melanoma helper peptide vaccine) | Recruiting | Phase I/II | Concurrent |
| NCT03088176 | Dabrafenib + trametinib | Talimogene Laherparepvec | Recruiting | Phase I | Concurrent |